| Multiple Sclerosis |
1 |
1 |
| Disability |
0 |
0.66 |
| Biomarker |
0 |
0.51 |
| Clinically Isolated Syndrome (CIS) |
0 |
0.36 |
| Secondary Progressive Multiple Sclerosis |
0 |
0.29 |
| Clinical Research |
0 |
0.15 |
| Primary Progressive Multiple Sclerosis |
0 |
0.15 |
| Relapsing Remitting Multiple Sclerosis |
0 |
0.15 |
| NHS |
0 |
0.11 |
| Clinical Management |
0 |
0.07 |
| Massachusetts |
0 |
0.07 |
| Multiple Sclerosis Risk |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Targeted Cancer Therapy |
0 |
0.07 |
| UK Site Content |
0 |
0.07 |
| Multiple Sclerosis Prognosis |
0 |
0.05 |
| Biologic Therapy |
0 |
0.03 |